[go: up one dir, main page]

Fuzzati-Armentero et al., 1998 - Google Patents

hu-PBL-SCID mice: an in vivo model of Epstein-Barr virus-dependent lymphoproliferative disease

Fuzzati-Armentero et al., 1998

View PDF
Document ID
3053216337670064949
Author
Fuzzati-Armentero M
Duchosal M
Publication year
Publication venue
Histology and histopathology

External Links

Snippet

The Epstein-Barr virus (EBV) exists in most humans as a lifelong latent infection established in hosl B cells after a primary viral encounter. In immunosuppressed il1llividuals, such as post-transplant patients, the presence of EBV-infected B cells may lead to IY III P hop r 0 I i …
Continue reading at www.hh.um.es (PDF) (other versions)

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/191—Tumor necrosis factors [TNF], e.g. lymphotoxin [LT], i.e. TNF-beta
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues ; Not used, see subgroups
    • C12N5/0602—Vertebrate cells
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICRO-ORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING OR MAINTAINING MICRO-ORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients

Similar Documents

Publication Publication Date Title
Fontana et al. Transforming growth factor-beta inhibits the generation of cytotoxic T cells in virus-infected mice.
CA2087525C (en) Adoptive immunotherapy with interleukin-7
Butler et al. DBA/1 mice expressing the human TNF-alpha transgene develop a severe, erosive arthritis: characterization of the cytokine cascade and cellular composition.
Franco et al. Pathogenetic effector function of CD4-positive T helper 1 cells in hepatitis B virus transgenic mice.
CN111658670B (en) Oncolytic adenoviral vectors and adoptive T cell therapeutic compositions and uses thereof
JP6395379B2 (en) Compositions and methods for modulating γc cytokine activity
JP7364237B2 (en) Method for activating T cells for cancer treatment
Ilan et al. Oral tolerization to adenoviral proteins permits repeated adenovirus‐mediated gene therapy in rats with pre‐existing immunity to adenoviruses
JP2009046512A (en) Methods and compositions for inhibiting tumor growth and enhancing immune responses
Barr et al. A role for plasmacytoid dendritic cells in the rapid IL‐18‐dependent activation of NK cells following HSV‐1 infection
Sharma et al. Natural immune functions
Abedi et al. Preventive effect of IgG from EBV‐seropositive donors on the development of human lympho‐proliferative disease in SCID mice
Haagmans et al. Tumor necrosis factor alpha promotes replication and pathogenicity of rat cytomegalovirus
Fuzzati-Armentero et al. hu-PBL-SCID mice: an in vivo model of Epstein-Barr virus-dependent lymphoproliferative disease
Guillerey et al. Systemic administration of IL‐33 induces a population of circulating KLRG1hi type 2 innate lymphoid cells and inhibits type 1 innate immunity against multiple myeloma
Murphy et al. Recombinant human growth hormone promotes human lymphocyte engraftment in immunodeficient mice and results in an increased incidence of human Epstein Barr virus-induced B-cell lymphoma
US8067227B2 (en) Viral vectors and the use of the same for gene therapy
Kanto et al. Neutralization of transforming growth factor β1 augments hepatitis C virus-specific cytotoxic T lymphocyte induction in vitro
SK12994A3 (en) Way of modulation of inflammation and the immunity function mediate by means of t-cells
US20100203009A1 (en) Pathway for Th-17 Cell Development and Methods Utilizing Same
US20170137782A1 (en) Method for producing b cell population
Veronesi et al. Lymphoproliferative disease in human peripheral‐blood‐mononuclear‐cell‐injected scid mice. II. Role of host and donor factors in tumor generation
US20130337001A1 (en) Immunogenic composition for treatment of hepatitis C, a method for preparing the composition and use thereof for treating hepatitis C
US20160106076A1 (en) Recombinant non-human mammalian model for hepatitis infection and immunopathogenesis
Sun et al. Human prolactin improves engraftment and reconstitution of human peripheral blood lymphocytes in SCID mice